Most data regarding the kidney effects of GLP-1 RAs come from cardiovascular outcome trials (CVOTs) enrolling patients with type 2 diabetes at high cardiovascular risk [12, 15] with a paucity of real-world data [18]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.